GlaxoSmithKline (GSK) and Pfizer announced the creation of a consumer healthcare joint venture, followed by the potential separation of the entity, which we expect will drive better synergies and unlock value for both companies, but we don't expect any significant changes to our fair value estimates for either company.
The companies expect close to £500 million in cost synergies, which seems reasonable. Additionally, we believe the potential separation of the new joint venture could unlock value for both Pfizer and Glaxo, as consumer healthcare companies trade at higher valuation multiples than Big Pharma firms.
While the timing of the transactions is not fully clear, the formation of the joint venture should be completed by the second half of 2019, and a separation of the joint venture could happen two to three years later. From a moat standpoint, the joint venture would boast strong brand power, with annual sales of close to £10 billion and well-known products, such as Theraflu, Excedrin, Advil, and Centrum.
We expect the robust brand power to support strong competitive advantages for the new entity. Additionally, we don't expect the potential separation of the joint venture from Glaxo and Pfizer to affect the moats of the remaining firms' drug and vaccine operations, as the consumer products contributed a smaller amount of profits to the overall companies.
From a dis-synergy perspective, the potential separation of the consumer entity would erase the financial benefit of prescription to over-the-counter switches, which has been successful for drugs like respiratory drug Flonase.
After the likely separation of the consumer entity from Glaxo and Pfizer, we expect capital to shift back to the drug companies through an IPO or by adding debt to the consumer unit in a spin-out. We expect both drug firms to use the capital to acquire smaller firms with mid- to late-stage drugs in development in areas of unmet medical need.
